Background The role of nitric oxide (NO) in reactive hyperemia (RH) is not well known. We investigated whether NO plays a role in RH in human forearm vessels by examining the effects of N0-monomethyl-L-arginine (L-NMMA), a blocker of NO synthesis, on reactive hyperemic flow.
Background The role of nitric oxide (NO) in reactive hyperemia (RH) is not well known. We investigated whether NO plays a role in RH in human forearm vessels by examining the effects of N0-monomethyl-L-arginine (L-NMMA), a blocker of NO synthesis, on reactive hyperemic flow.
Methods and Results Forearm blood flow (FBF) was measured by strain-gauge plethysmography with a venous occlusion technique. The left brachial artery was cannulated for drug infusion and direct measurement of arterial pressure. To produce RH, blood flow to the forearm was prevented by inflation of a cuff on the upper arm to suprasystolic pressure for intervals of 3 and 10 minutes. After the release of arterial occlusion (AO), FBF was measured every 15 seconds for 3 minutes. Resting FBF was 4.3+0.3 mL* min 100 mLbefore 3 minutes of AO and 4.1+0.6 mL* min'-* 100 mL`1 before 10 minutes of AO. FBF increased to 32.3± 1.9 and 38.2+3.1 mL-min'* 100 mL-1 immediately after 3 and 10
Raeactive hyperemia after temporary interruption of blood flow is thought to result from an interplay between physical (myogenic) and local metabolic factors.1 Of the metabolic factors, prostaglandins,2-6 adenosine,6-8 and ATP-sensitive potassium channels9,10 play an important role in reactive hyperemia.
The endothelium plays an important role in control of vascular tone." Nitric oxide (NO) is produced in the process of conversion of L-arginine to L-citrulline by NO synthase in endothelial cells.12-1 NO is thought by many to be a major component of endothelium-derived relaxing factor (EDRF) and a potent vasodilator. The role of NO in control of vascular tone during reactive hyperemia has been studied only in animals. 16, 17 Previous results suggest that in the coronary circulation of the dog, NO does not play a role in peak reactive hyperemia but plays a significant role during the late phase of reactive hyperemia.16 In the peripheral circulation of the rat skeletal muscle, it has been shown that NO does not play a significant role in peak reactive hyperemia.18,19 However, little is known about the role of NO in reactive hyperemia at the peak and during the late phase in the peripheral circulation in humans.
minutes of AO, respectively, and gradually decayed (n= 13). Intra-arterial infusion of L-NMMA (4 ,umol/min for 5 minutes) decreased baseline FBF (P<.01) without changes in arterial pressure. L-NMMA did not affect the peak reactive hyperemic FBF after 3 and 10 minutes of AO. L-NMMA significantly decreased total reactive hyperemic flow (flow debt repayment) by 20% to 30% after 3 and 10 minutes of AO. Simultaneous infusion of L-arginine (a precursor of NO) with L-NMMA reversed the effects of L-NMMA.
Conclsions Our results suggest that NO plays a minimal role in vasodilation at peak RH but plays a modest yet significant role in maintaining vasodilation after peak vasodilation. Our results also suggest that reactive hyperemia in human forearms is caused largely by mechanisms other than NO. (Circulation. 1994;90:2285-2290.)
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In this study, we examined the role of NO in the control of vascular tone during reactive hyperemia in human forearm vessels by studying the effects of NG-monomethyl-L-arginine (L-NMMA), a blocker of NO synthesis, on forearm blood flow during reactive hyperemia.
Methods

General Procedure
Subjects were healthy male students (21 to 28 years old) at the university who volunteered for the study. The protocol was explained, and informed written consent was obtained from each subject. The study was approved by the Ethical Committee for Human Investigation at our institution. The study was done with subjects in a supine position in an air-conditioned room with room temperature of about 25°C to 26°C. Under local anesthesia with 2% procaine, the left brachial artery was cannulated with a 20-gauge intravascular over-the-needle poly(tetrafluoroethylene) cannula 
Reactive Hyperemia
To produce reactive hyperemia, blood flow to the forearm was prevented by inflation of the cuff on the upper arm to suprasystolic pressure. 2223 The duration of arterial occlusion was 10 minutes in 13 subjects and 3 minutes in 8 subjects. It has been shown that maximal vasodilation of forearm resistance vessels is achieved during peak reactive hyperemia after 10 minutes of arterial occlusion.2224-26 After release of arterial occlusion, forearm blood flow was measured at 5 seconds after release and every 15 seconds thereafter for 3 minutes. Forearm blood flow and arterial pressure were monitored and recorded continuously during reactive hyperemia. The peak flow during reactive hyperemia is markedly greater than control blood flow (Fig 1) . Therefore, to accurately calculate forearm blood flow during reactive hyperemia, hyperemic flow was recorded at a paper speed of 30 cm/min, which was three times faster than the speed for control flow recordings. Flow debt repayment was defined as the curve of area under the flow versus time during reactive hyperemia above baseline flow for 3 minutes.9,24,27 Protocols Experiment 1 After cannulas and a strain-gauge plethysmograph were placed, at least 15 minutes was allowed for subjects to become accustomed to the study conditions before the protocol was begun. Forearm blood flow was measured at rest and during reactive hyperemia for 3 minutes after 10 minutes of arterial occlusion (n= 13) . After recovery of reactive hyperemia when forearm blood flow had returned to the baseline level, L-NMMA was infused intra-arterially at a dose of 4 ,umol/min for 5 minutes while forearm blood flow and arterial pressure were recorded. We have shown previously that this dose of L-NMMA significantly increases forearm vascular resistance but does not alter arterial pressure. 28 Immediately after infusion of L-NMMA was stopped, blood flow to the forearm was prevented for 10 minutes. After release of arterial occlusion, forearm blood flow and arterial pressure were recorded for 3 minutes. In 8 of the 13 subjects, we examined whether L-arginine reversed the effects of L-NMMA on forearm blood flow. At least 30 minutes after release of arterial occlusion, L-NMMA (4 ,mol/min) and L-arginine (8 mg/min; about 40 ,gmol/min) were infused simultaneously and intra-arterially for 5 minutes while forearm blood flow and arterial pressure were recorded. Immediately after infusion of L-NMMA with L-arginine was stopped, 10 minutes of arterial occlusion was repeated. After releases of arterial occlusion, forearm blood flow and arterial pressure were recorded for 3 minutes.
Experiment 2
In this experiment, 3 minutes of arterial occlusion was applied in another group of subjects (n=8). All procedures and measurements were done in the same way as experiment 1. 
Results
Reactive Hyperemia
Immediately after release of 10 or 3 minutes of arterial occlusion, forearm blood flow increased and forearm vascular resistance decreased (Tables 1 and 2 Tables 1 and 2 ). L-NMMA did not alter arterial pressure (P=.75) and heart rate (P=.45) (data not shown). L-NMMA did not affect peak forearm blood flow (P=.19 and .84, respectively) and minimal forearm vascular resistance (P=.11 and .85, respectively) during reactive hyperemia after release of 10 (n=13) or 3 minutes (n=8) of arterial occlusion (Tables 1 and 2 ). L-NMMA did not change the time points at which the peak flow occurred in each subject. L-NMMA reduced blood flow during the midto-late phase of reactive hyperemia (P<.01) (Figs 2 and 3, left) and flow debt repayment (P<.01) ( Tables 1 and  2 ) after 10 minutes or 3 minutes of arterial occlusion.
Effects of L-NMMA Plus L-Arginine
Simultaneous infusions of L-NMMA and L-arginine reversed the vasoconstricting effects of L-NMMA on forearm vessels at rest (Tables 1 and 2 ) and during hyperemia (Figs 2 and 3, right) and reversed the effects of L-NMMA on flow debt repayment (Tables 1 and 2 ).
Discussion
Although several previous investigators have examined the role of NO in reactive hyperemia in animals, this is the first study in which the role of NO in reactive hyperemia was examined in humans. The major findings of this study are as follows. First, intra-arterial infusion of L-NMMA (a blocker of formation of endotheliumderived NO) decreased forearm blood flow and increased forearm vascular resistance at rest. Second, L-NMMA did not affect peak forearm vasodilation during reactive hyperemia. Third, L-NMMA significantly (by 20% to 30%) decreased flow debt repayment during reactive hyperemia. Fourth, L-arginine reversed the effects of L-NMMA. These results suggest that although NO plays a significant role in control of vascular resistance at rest, the role of NO in control of vascular resistance during peak reactive hyperemia is minimal. Our results also suggest that NO contributes to reactive hyperemia at the mid-to-late phase, but the magnitude of its contribution is small.
Role of NO in Maximal Vasodilation During Reactive Hyperemia
It has been suggested that NO plays a minimal role in peak vasodilation in the coronary circulation of animals. Kostic and Schrader17 reported in the coronary circulation of the isolated pig heart that nitro-L-arginine methyl ester (an inhibitor of NO synthesis) did not affect maximal blood flow after brief coronary occlusion. Yamabe et al16 reported similar findings in the coronary circulation of the dog. In the peripheral circulation, it has been shown that in the rat skeletal muscle, L-NMMA did not affect peak arteriolar dilation and flow velocity during peak reactive hyperemia. 18, 19 In this study, forearm blood flow and vascular resistance at peak reactive hyperemia after 3 and 10 minutes of arterial occlusion were not different before and after intra-arterial infusion of L-NMMA. Moreover, L-NMMA did not change the time points at which the peak flow occurred in each subject. Our findings are consistent with those in animals16-19 and suggest that NO plays a minimal role in vasodilation at peak reactive hyperemia in the human forearm.
To interpret these results, it is important to consider the efficacy of L-NMMA at the dose used in this study in blocking the synthesis of NO in the forearm vessels. We demonstrated in this and a previous study28 that L-NMMA at 4 gmol/min caused vasoconstriction at rest, which was reversed by L-arginine. In the previous study, we examined the inhibitory effect of L-NMMA at this dose on endothelium-dependent forearm vasodilation caused by acetylcholine at 4 and 12 ,ug/min, which increased forearm blood flow to approximately 13 and 30 mL* min-. 100 mL-1, respectively, before L-NMMA.28 L-NMMA at this dose almost completely inhibited modest vasodilation induced by intra-arterial infusion of acetylcholine at a low dose and inhibited by 50% vasodilation induced by acetylcholine at a high dose. 28 Thus, we consider that L-NMMA at this dose should have altered the peak reactive hyperemic flow if NO contributed to peak reactive hyperemia. In fact, L-NMMA did not alter the peak reactive hyperemic flow after 3 minutes of arterial occlusion but attenuated comparable increases in flow at the mid-to-late phase of reactive hyperemia after 10 minutes of arterial occlusion (Figs 2 and 3) . These results strongly suggest that failure of L-NMMA to alter vasodilation at peak reactive hyperemia is not due to the inadequate dose of L-NMMA and that NO plays a minimal role at peak reactive hyperemia. We elected not to give higher doses of L-NMMA because of a possible increase in systemic blood pressure and vasoconstriction in other vascular beds, particularly in the brain. In this study, L-NMMA reduced blood flow during the mid-to-late phase of reactive hyperemia and decreased flow debt repayment. L-Arginine reversed the inhibitory effect of L-NMMA. It is conceivable that the effect of L-NMMA on forearm blood flow at rest continued unchanged during reactive hyperemia; ie, the attenuated increases in forearm blood flow after L-NMMA during the mid-to-late phase of reactive hyperemia may have been due to decreased forearm blood flow by L-NMMA at rest. However, the differences in forearm blood flow during reactive hyperemia were not only due to the differences in forearm blood flow at rest, because the differences were much greater during reactive hyperemia than at rest. Moreover, flow debt repayment after L-NMMA was smaller than that before L-NMMA. These ATP-sensitive potassium channels may play a role in reactive hyperemia in human forearm vessels. However, contributions of prostaglandins, adenosine, or ATPsensitive potassium channels to reactive hyperemia in the forearm were not examined in this study.
In summary, our results may suggest that the role of NO in peak vasodilation during the early phase of reactive hyperemia is minimal but is modest yet significant during the mid-to-late phase of reactive hyperemia in human forearm vessels.
